Digene Infrastructure Scale-Up For DNA Pap Could Follow Failed Cytyc Merger
This article was originally published in The Gray Sheet
Executive Summary
Digene may decide to expand its sales infrastructure for marketing the HPV DNA Pap test as a primary screen for cervical cancer if its pending merger with Cytyc does not occur
You may also be interested in...
Digene Physician Detailing Pact With PDI Tops DNAwithPap Launch Strategy
Digene does not plan to extend a co-promotion pact with Cytyc for its DNAwithPap test after signing on PDI to set up a U.S. physician detailing organization
Digene Physician Detailing Pact With PDI Tops DNAwithPap Launch Strategy
Digene does not plan to extend a co-promotion pact with Cytyc for its DNAwithPap test after signing on PDI to set up a U.S. physician detailing organization
ThinPrep Pricing Level Improvement Drives Cytyc Q1 Revenues To $72.6 Mil.
Cytyc anticipates a second quarter launch for the ThinPrep automated imaging and review system, which is used with the company's cervical cancer screening test